DDInter837 DDInter172
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®.
Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. It is approved for the treatment of rheumatoid arthritis. Belatacept selectively blocks the process of T-cell activation. It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diiodohydroxyquinoline
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Cyclophosphamide
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Golimumab may lead to a major life threatening interaction when taken with Cyclophosphamide
Golimumab may lead to a major life threatening interaction when taken with Avapritinib